Literature DB >> 9286768

Tumor-induced osteomalacia: clinical and basic studies.

E Shane1, M Parisien, J E Henderson, D W Dempster, F Feldman, M A Hardy, J F Tohme, A C Karaplis, T L Clemens.   

Abstract

A patient with classic clinical and biochemical features of tumor-induced osteomalacia (hypophosphatemia, phosphaturia, and undetectable serum concentrations of 1,25-dihydroxyvitamin D [1,25(OH)2D]) was studied before and after resection of a benign extraskeletal chondroma from the plantar surface of the foot. Presurgical laboratory evaluation was notable for normal serum concentrations of calcium, intact parathyroid hormone (PTH), parathyroid hormone-related protein (PTHrP), and osteocalcin, increased serum alkaline phosphate activity, and frankly elevated urinary cyclic adenosine monophosphate (cAMP) and pyridinium cross-link excretion. Quantitative histomorphometry showed severe osteomalacia and deep erosions of the cancellous surface by active osteoclasts. After resection, serum 1,25(OH)2D normalized within 24 h, while renal tubular phosphorus reabsorption and serum phosphorus did not normalized until days 2 and 3, respectively; serum Ca declined slightly, and serum intact PTH, osteocalcin, and urinary pyridinium cross-link excretion increased dramatically. Urinary cAMP excretion declined immediately after resection and then began to increase concomitant with the increase in serum intact PTH. A second bone biopsy taken 3 months after resection demonstrated complete resolution of the osteomalacia, increased mineral apposition rate (1.09 mu/day), resorption surface (9.2%), mineralizing surface (71%), and bone formation rate (0.83 mm3/mm2/day), and marked decrease in cancellous bone volume (13.1%) and trabecular connectivity compared with first biopsy. Tumor extracts did not affect phosphate transport in renal epithelial cell lines or 1 alpha-hydroxylase activity in a myelomonocytic cell line. The patient's course suggests that the normal 1,25(OH)2D and phosphorus metabolism is due to a tumor product that may be acting via stimulation of adenylate activity. Increased bone resorption prior to surgical resection suggests that the tumor may also produce an osteoclast activator. The rise in resorption surface and pyridinium cross-link excretion, increase in serum osteocalcin and bone mineralization, normalization of osteoid width, and fall in cancellous bone volume after resection are consistent with healing of osteomalacia by rapid remodeling.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9286768     DOI: 10.1359/jbmr.1997.12.9.1502

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  11 in total

1.  Reports of 17 Chinese patients with tumor-induced osteomalacia.

Authors:  Wei-Jia Yu; Jin-Wei He; Wen-Zhen Fu; Chun Wang; Zhen-Lin Zhang
Journal:  J Bone Miner Metab       Date:  2016-04-16       Impact factor: 2.626

2.  Following the forgotten phosphorus.

Authors:  Lekshmi T Nair; Leslie Dodd; Thomas J Weber
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

Review 3.  Phosphaturic mesenchymal tumor, mixed connective tissue variant, of the mandible: report of a case and review of the literature.

Authors:  Victoria L Woo; Regina Landesberg; Erik A Imel; Steven R Singer; Andrew L Folpe; Michael J Econs; Taeyun Kim; Lara R Harik; Thomas P Jacobs
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2009-10-14

4.  Tumor localization and biochemical response to cure in tumor-induced osteomalacia.

Authors:  William H Chong; Panagiota Andreopoulou; Clara C Chen; James Reynolds; Lori Guthrie; Marilyn Kelly; Rachel I Gafni; Nisan Bhattacharyya; Alison M Boyce; Diala El-Maouche; Diana Ovejero Crespo; Richard Sherry; Richard Chang; Felasfa M Wodajo; Gad B Kletter; Andrew Dwyer; Michael T Collins
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

Review 5.  En bloc resection for treatment of tumor-induced osteomalacia: a case presentation and a systematic review.

Authors:  Tong Meng; Wang Zhou; Bo Li; Huabin Yin; Zhenxi Li; Lei Zhou; Jinhai Kong; Wangjun Yan; Xinghai Yang; Tielong Liu; Dianwen Song; Jianru Xiao
Journal:  World J Surg Oncol       Date:  2015-05-08       Impact factor: 2.754

6.  Tumor induced osteomalacia secondary to anaplastic thyroid carcinoma: A case report and review of the literature.

Authors:  Ejigayehu G Abate; Victor Bernet; Cherise Cortese; Hillary W Garner
Journal:  Bone Rep       Date:  2016-02-17

7.  MicroRNA expression in a phosphaturic mesenchymal tumour.

Authors:  Darrell Green; Irina Mohorianu; Isabelle Piec; Jeremy Turner; Clare Beadsmoore; Andoni Toms; Richard Ball; John Nolan; Iain McNamara; Tamas Dalmay; William D Fraser
Journal:  Bone Rep       Date:  2017-09-06

Review 8.  A rare combination of tumor-induced osteomalacia caused by sinonasal glomangiopericytoma and coexisting parathyroid adenoma: case report and literature review.

Authors:  Agnieszka Brociek-Piłczyńska; Dorota Brodowska-Kania; Kornel Szczygielski; Małgorzata Lorent; Grzegorz Zieliński; Piotr Kowalewski; Dariusz Jurkiewicz
Journal:  BMC Endocr Disord       Date:  2022-01-28       Impact factor: 2.763

9.  Tumor-induced osteomalacia caused by primary fibroblast growth factor 23 secreting neoplasm in axial skeleton: a case report.

Authors:  Gunjan Y Gandhi; Aashish A Shah; Kevin J Wu; Vivek Gupta; Ali Reza Shoraka
Journal:  Case Rep Endocrinol       Date:  2012-12-17

Review 10.  Phosphaturic mesenchymal tumor and related wound problem.

Authors:  Xian Xiao; Xiaofang Sun; Pengwen Ni; Yao Huang; Ting Xie
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.